Source comparison
Ipamorelin vs Sermorelin: Research Application Comparison
Receptor Target GHS-R1a (ghrelin receptor) GHRH receptor (pituitary) Ipamorelin's dual hypothalamic-pituitary action better models endogenous ghrelin signalling Pulse Duration 2.5–3 hours (sustained) 90–120 minutes (sharp peak) Ipamorelin reduces temporal samp
This comparison does not assign a generated winner or score.
- Receptor Target
- GHS-R1a (ghrelin receptor)
- GHRH receptor (pituitary)
- Ipamorelin's dual hypothalamic-pituitary action better models endogenous ghrelin signalling
- Pulse Duration
- 2.5–3 hours (sustained)
- 90–120 minutes (sharp peak)
- Ipamorelin reduces temporal sampling sensitivity in multi-hour protocols
- Cortisol Impact
- None detected at standard doses
- Transient elevation possible at high doses
- Ipamorelin eliminates HPA axis confounding in stress-sensitive models
- Prolactin Impact
- None
- None (direct pathway)
- Both are prolactin-neutral. No differential advantage
- Desensitisation
- Slower (7–10 days chronic use)
- Faster (3–5 days chronic use)
- Ipamorelin supports longer continuous protocols without tachyphylaxis
- Half-Life
- ~2 hours
- ~10 minutes
- Sermorelin requires more frequent dosing for sustained exposure
- Sermorelin's short half-life (10 minutes) means it must be administered more frequently or combined with a peptidase inhibitor to maintain therapeutic levels. Ipamorelin's longer half-life (2 hours) allows for less frequent dosing while maintaining consistent plasma concentrations.